Patients: Children with severe sepsis in the Sepsis PRevalence, OUtcomes, and Therapies study. Interventions: None. Measurements and Main Results: One hundred two (21%) of 493 patients had severe acute kidney injury. More than twice as many patients with severe acute kidney injury died or developed new moderate disability compared with those with no/mild acute kidney injury (64% vs 30%; p < 0.001). Severe acute kidney injury was independently associated with death or new moderate disability (adjusted odds ratio, 2.5; 95% CI, 1.5-4.2; p = 0.001) after adjustment for age, region, baseline disability, malignancy, invasive mechanical ventilation, albumin administration, and the pediatric logistic organ dysfunction score. Conclusions: In a multinational cohort of critically ill children with severe sepsis and high mortality rates, septic acute kidney injury is independently associated with further increased death or new disability. (Crit Care Med 2016; 44:2241-2250) Key Words: acute kidney injury; critical care outcomes; epidemiology; pediatric intensive care units; renal replacement therapy; sepsis S epsis is a major precipitant of critical illness in children. Current data estimate that 8% of children in PICUs around the world have severe sepsis at a given time (1) . The prevalence of sepsis in children is increasing, and with improvements in sepsis-related mortality, functional outcomes in survivors are increasingly important (2, 3) . One common comorbidity of severe sepsis is acute kidney injury (AKI), comprising up to half of critical illness-associated AKI in adults (4) (5) (6) . AKI occurs in approximately 16% of children in PICUs (7) , but the true prevalence of septic AKI is unknown. Few studies prospectively describe the outcomes of children suffering AKI exclusively in the context of sepsis. Most instead evaluate the outcome after AKI in the general PICU population (7) (8) (9) (10) (11) . Functional status and long-term health of survivors of critical illness are increasingly viewed as highly meaningful patient-centered outcomes (12, 13) . Septic AKI is associated with increased morbidity and mortality compared with nonseptic AKI (4, 14, 15) in adults. Data on functional outcomes of children with septic AKI do not exist.
The Sepsis PRevalence, OUtcomes, and Therapies (SPROUT) point prevalence study enrolled patients with severe sepsis in 128 PICUs across 26 countries worldwide (1). Hospital mortality was 25%, and 17% of survivors had new moderate or worse disability at hospital discharge. We used data from the SPROUT study to determine the global prevalence of pediatric septic AKI. We evaluated the association of septic AKI with the composite outcome of new disability or mortality to determine the additive impact of AKI in the setting of severe sepsis.
METHODS
SPROUT was a prospective, cross-sectional point prevalence study performed at 128 PICUs in 26 countries (1). PICU patients were screened for severe sepsis according to the "2005 International Pediatric Sepsis Consensus Conference" criteria (16) using data from the 24 hours preceding the study day, yielding a study cohort with active severe sepsis. For this analysis, patients with a prior history of renal disease were excluded. Ethics approval was obtained at all sites. Written consent was required at three sites. All other sites granted waiver of informed consent.
Data Collection
Patient demographics were collected from the time of PICU admission. Vital signs, laboratory data, and therapeutic interventions provided were collected within a 48-hour window around the study day. Systolic blood pressure was categorized as less than or greater than fifth percentile for age and gender assuming 50th percentile for height (17) . Severity of illness was measured by the Pediatric Index of Mortality-3 (PIM3) score (18) at PICU admission. The presence of multiple-organ dysfunction syndrome (MODS) was assessed on the day of severe sepsis recognition (first hospital day on which patients met consensus criteria for severe sepsis). The degree of organ dysfunction was measured by the Pediatric Logistic Organ Dysfunction (PELOD) score (19) without the renal component of the score (PELOD-R) in the 48-hour window around the study day. Patients were followed up until the hospital discharge to determine outcomes and censored at 90 days after the study day if still hospitalized.
AKI Definition
AKI was defined using the Kidney Disease Improving Global Outcomes (KDIGO) criteria (20) (supplemental methods, Supplemental Digital Content 1, http://links.lww.com/CCM/ C3). Patients were categorized as having no AKI or stage 1 AKI ("no/mild AKI" group) versus stage 2 or 3 AKI ("severe AKI" group) using the maximum serum creatinine measured in the 48-hour data collection window. Baseline renal function was assumed to be normal as children with preexisting renal comorbidities were excluded. A baseline serum creatinine value was assigned to all patients using average age-and gender-based norms as previously described (9, 21, 22) .
Outcomes
The primary outcome was the composite of 1) death or 2) new moderate or worse disability, measured by a Pediatric Overall Performance Category (POPC) score of 3 or higher and increased by at least 1 category from baseline (12) . The POPC ordinal scale (1 = good overall performance, 2 = mild disability, 3 = moderate disability, 4 = severe disability, 5 = coma or vegetative state, and 6 = brain death) was measured at baseline using PICU admission documentation and at hospital discharge or 90 days after the study day to assess change in functional status (23) . A priori defined secondary outcomes included PICU and hospital mortality censored at 90 days; PICU and hospital length of stay; and ventilator-free and vasoactive infusion-free days of 28 days from the day of severe sepsis recognition.
Statistical Analysis
Data were analyzed using STATA (version 12.1; College Station, TX). Data are presented as medians with interquartile ranges for continuous variables and frequencies with proportions for categorical variables. Comparisons between groups were performed using the Wilcoxon signed rank test for continuous variables and Fisher exact or chi-square test for proportions. Multivariable logistic regression was performed to test the independent association of AKI with binary outcomes, and negative binomial regression was used for count outcomes (Supplemental Methods, Supplemental Digital Content 1, http://links.lww. com/CCM/C3). Based on a nonsignificant trend noted in the univariate association of AKI with new moderate disability in survivors, a post hoc analysis of a trichotomous outcome separating death and disability was performed using multinomial regression (Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/CCM/C3).
RESULTS

AKI Prevalence
In the SPROUT study, 6,925 patients were screened over 5 days and 569 were identified with severe sepsis (1) . For this analysis, 493 patients met inclusion criteria (Supplemental Fig. 1 
Septic AKI Was Associated With Death/Disability
The primary outcome, death or new moderate or worse disability, occurred over twice as often in those with severe AKI compared with patients with no/mild AKI (64% vs 30%; p < 0.001; Table 2 ). POPC score worsened in 37% of survivors with severe AKI and in 26% of survivors with no/mild AKI ( Fig. 1) . New moderate or worse disability occurred in 24% of survivors with severe AKI versus 15% of survivors with no/mild AKI (p = 0.105). Unadjusted PICU and hospital mortality were nearly three times higher in the severe AKI group, and these patients had fewer ventilator-free and vasoactive infusion-free days in the 28 days following severe sepsis recognition ( Table 2) .
Univariable logistic regression was used to identify variables associated with AKI (Supplemental Table 1 Table 2 , Supplemental Digital Content 1, http://links.lww. com/CCM/C3). Using multivariable regression modeling, severe AKI remained independently associated with death or new moderate or worse disability after adjustment for age, geographic region, history of malignancy, baseline POPC score, use of invasive mechanical ventilation, albumin administration, and PELOD-R score (adjusted odds ratio [OR], 2.49; 95% CI, 1.48-4.19; p = 0.001). In sensitivity analyses, the presence of severe AKI by urine output criteria or any AKI (stages 1-3) was also independently associated with death or new moderate dis-ability (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/C3). In addition, severe AKI was independently associated with PICU mortality and hospital mortality after adjustment for these variables (Table 3) . Similarly, severe AKI was independently associated with fewer vasoactive infusion-free days (adjusted β, -0.27; 95% CI, -0.48 to -0.05; p = 0.015) after adjustment for age, geographic region, use of invasive mechanical ventilation, blood product administration, and PELOD-R score. The association of AKI with fewer ventilator-free days was no longer statistically significant (adjusted β, -0.23; 95% CI, -0.56 to 0.09; p = 0.158) after adjustment for confounders (age, geographic region, number of vasoactive infusions, blood product administration, and PELOD-R score).
A post hoc analysis was performed to evaluate the independent association of severe AKI with new moderate or worse disability and mortality separately, using the trichotomous outcome alive with no or mild new disability, alive with new moderate or worse disability, or deceased. In this analysis, severe AKI remained significantly associated with mortality but was not significantly associated with new moderate or worse disability in survivors (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/C3).
Patients With Severe AKI Had Higher Illness Severity and Complexity
PIM3 score at PICU admission was higher in patients with severe AKI (Table 1 ). More patients with severe AKI had MODS at the time of sepsis recognition compared with those with no/mild AKI, and patients with severe AKI had a higher degree of organ dysfunction as measured by the PELOD-R score on the study day (Table 1) . Respiratory, hematologic/immunologic, and neoplastic comorbidities and solid organ or hematopoietic cell transplant were more common in patients with severe AKI (Table 1) .
In keeping with more clinical findings of shock in the severe AKI group (Table 1) , these patients were treated more often with infusions of vasoactive agents, albumin, and blood products on the study day ( Table 4) . Although albumin and blood product administration was quite common in the study (26% and 43%, respectively, of all patients in the cohort), the use of synthetic colloid was rare at 4% overall and did not differ in patients with severe AKI and those with no/mild AKI (Table 4 ).
Geographic Differences
Severe AKI was least frequent in North and South America (16-19%) and most frequent in Europe, Asia, and Australia/ New Zealand (29-32%) (Supplemental Fig. 2 
DISCUSSION
Severe AKI was present in approximately 20% pediatric patients with severe sepsis and was independently associated with poor outcomes. Children with sepsis-associated severe AKI had more than double the odds of death or new moderate disability at hospital discharge than children with severe sepsis and no or mild AKI. This is the first study to evaluate the association of AKI with a general measure of disability in survivors of pediatric severe sepsis, which is attributable for much of AKI encountered in PICUs. Further research in this area is needed as a post hoc analysis could not confirm a significant association between AKI and new disability. These results suggest that severe AKI is associated with poorer functional outcomes in survivors of pediatric severe sepsis. There is increasing recognition of the relevance of patient-centered functional outcomes in pediatric severe sepsis research (24, 25) , and there is a growing body of literature describing methodology to study these outcomes (12, 13) . Long-term follow-up of survivors of pediatric critical illness have shown an association with AKI and chronic kidney disease (26, 27) but have not looked into other measures of overall patient function. Evidence from nonseptic animal models of AKI support the extrarenal effects of injury on other vital organs, including the brain (28) . Rodent models of renal ischemia show impairment in motor activity, disruption of the blood-brain barrier, and effects on the hippocampus, which is important for learning (29, 30) . These studies suggest that investigation of functional outcomes in patients with AKI should be prioritized. This study demonstrated that children with severe sepsis and severe AKI had an additive increase in risk of death or disability, on top of that imparted by severe sepsis alone. Patients with severe AKI in this study had higher illness severity and were treated more frequently with vasoactive infusions, mechanical ventilation, and colloid administration. The association of severe AKI and poorer outcome, however, persisted after adjusting for increased patient complexity and illness severity in our primary analysis. In post hoc analysis, the association of AKI with increased new disability in survivors was not statistically significant when analyzed using trichotomous outcomes, suggesting that mortality is a large driver of our results. Although this study was not powered for such a trichotomous analysis, this finding indicates that further research is needed to confirm our conclusions. Previous studies on pediatric AKI survivors were confined to renal outcomes, demonstrating that patients were likely to develop signs of chronic kidney disease as early as 1 year after discharge (27) . Up to 25% of patients leave the PICU with abnormal serum creatinine values (9) although only a minority return for longterm nephrology follow-up (26) . Our data suggest that AKI survivors are also at risk of new disability, further underscoring the importance of long-term follow-up.
In this international cohort of children with severe sepsis, severe AKI was most common in Australia/New Zealand, Asia, and Europe and least common in North and South America. The proportion of children with severe AKI treated with RRT varied across geographic region from 0% to 75%. These geographic differences in AKI prevalence and practice variability in RRT use possibly reflect varying PICU patient populations and PICU admission criteria and could be a natural setting for comparative effectiveness work in septic AKI.
There are multiple areas for further study of pediatric septic AKI. No targeted therapies for septic AKI exist, and optimal treatment of pediatric septic AKI is unknown. The etiology of septic AKI is multifactorial rather than simply a secondary insult because of ischemia from shock (31) (32) (33) . Poor perfusion, pro-and antiinflammatory mediators, and microthrombosis likely contribute synergistically to necrotic and apoptotic renal cell death, leading to AKI (33) (34) (35) . Implementation of emergency department-based resuscitation bundles with protocolized fluid resuscitation and early antibiotics along with appropriate escalation of vasopressor support has been associated with decreased AKI development in children with septic shock (36) . The KDIGO AKI management bundle for patients with AKI, which includes ensuring volume status and perfusion pressure, consideration of functional hemodynamic monitoring, and consideration of RRT for stage 2 or greater AKI (37), needs to be tested. Controversy remains over the use of colloids versus crystalloids for fluid resuscitation in severe sepsis, and adult evidence shows increased risk of AKI with synthetic colloid use (38) (39) (40) (41) . Patients with severe AKI in this study received more colloid; however, this dataset was not designed to compare the use of crystalloid versus colloid, and few patients received synthetic colloids, limiting comparisons within our cohort. A limitation of this study is that baseline serum creatinine data were not collected, thus limiting the cohort to patients with no history of kidney disease. Baseline creatinine was assigned using age and gender norms, an accepted methodology for dealing with missing baseline creatinine data in children (9, 22) . Assigning a baseline estimated glomerular filtration rate of 120 mL/min/1.73 m 2 (11, 42) and using the Schwartz formula to assign baseline creatinine values with multiple imputation for missing height data yielded similar results (data not shown). In addition, we categorized patients as severe (stage 2 or 3) versus no/mild AKI (no or stage 1) to minimize misclassification bias because of unknown baseline renal function.
AKI was defined by KDIGO criteria as this is the most recently described AKI classification, is applicable to children and adults, and does not require height data. Other AKI staging criteria exist with similar but not identical definitions, yielding different prevalences of AKI based on definition (43), possibly limiting comparisons across studies. The primary outcome was evaluated at hospital discharge and censored at 90 days, and thus, not all patients were followed up for 90 days, possibly leading to misclassification bias as new disability at discharge may have resolved by 90 days. This should bias the results toward the null and therefore does not alter the study conclusions.
Other limitations include the point prevalence design, in which the majority of data collection occurred during a brief, cross-sectional time window. This could result in underestimation of the frequency of AKI. The design allows only for measurement of associations between AKI and other clinical variables at the time of the data collection window, precluding attempts to establish exposures leading to AKI. However, patients were followed up prospectively for outcomes, and the association of AKI with outcome was adjusted for multiple factors, such as preexisting comorbidities, PELOD-R, and therapeutic interventions.
CONCLUSIONS
Severe AKI is an independent risk factor for death or new moderate disability, a patient-centered functional outcome. Sixty-four percent of those with severe AKI died or developed new moderate or worse disability. Septic AKI survivors need long-term follow-up of renal function and other organ systems impacted by septic AKI. Future study with longer follow-up in pediatric septic AKI survivors is needed to confirm the association of AKI and disability we observed.
